RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000072.xml
Semin Reprod Med 2009; 27(4): 306-315
DOI: 10.1055/s-0029-1225258
© Thieme Medical Publishers
DOI: 10.1055/s-0029-1225258
Androgens in Polycystic Ovary Syndrome: The Role of Exercise and Diet
Francesco Giallauria1 , Stefano Palomba2 , Carlo Vigorito1 , Maria Giovanna Tafuri3 , Annamaria Colao4 , Gaetano Lombardi4 , Francesco Orio4 , 5- 1Department of Clinical Medicine, Cardiovascular and Immunological Sciences, University of Naples “Federico II,” Naples, Italy
- 2Department of Obstetrics and Gynaecology, University of Catanzaro “Magna Graecia,” Catanzaro, Italy
- 3Teaching and Methods of Sportive Activity, Faculty of Exercise Sciences, University of Naples “Parthenope,” Naples, Italy
- 4Department of Molecular & Clinical Endocrinology and Oncology, University of Naples “Federico II,” Naples, Italy
- 5Endocrinology, Faculty of Exercise Sciences, University of Naples “Parthenope,” Naples, Italy
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
15. Juni 2009 (online)
ABSTRACT
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women and is characterized by chronic ovulatory dysfunction and hyperandrogenism. Clinical studies have shown that hyperandrogenism is linked with insulin resistance/metabolic syndrome in PCOS women. This review article summarizes the several potential mechanisms for the association of androgen excess with insulin resistance, including both direct and indirect actions of androgens on insulin target tissues. This review article also focuses on the beneficial effects of exercise training and diet on glucose metabolism and hyperandrogenism in PCOS women, pointing out that whether in conjunction with pharmacotherapy or as a stand-alone treatment, diet and exercise training represent a fundamental strategy in the treatment of PCOS women.
KEYWORDS
Polycystic ovary syndrome - exercise training - diet - hyperandrogenism - insulin resistance
REFERENCES
- 1 Ehrmann D A. Polycystic ovary syndrome. N Engl J Med. 2005; 352 1223-1236
- 2 Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005; 90 4650-4658
- 3 Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008; 10 e3
- 4 The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81 19-25
- 5 Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown). 2008; 9 987-992
- 6 Hoffman L K, Ehrmann D A. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2008; 4 215-222
- 7 Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes (Lond). 2007; 31(Suppl 2) S8-S13; discussion S31–S32
- 8 Schröder A K, Tauchert S, Ortmann O, Diedrich K, Weiss J M. Insulin resistance in patients with polycystic ovary syndrome. Ann Med. 2004; 36 426-439
- 9 Chen M J, Yang W S, Yang J H, Chen C L, Ho H N, Yang Y S. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension. 2007; 49 1442-1447
- 10 Orio Jr F, Giallauria F, Palomba S et al.. Cardiopulmonary impairment in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91 2967-2971
- 11 Orio Jr F, Palomba S, Giallauria F, Colao A, Vigorito C. Impaired cardiopulmonary parameters in young women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007; 66 152-153
- 12 Giallauria F, Palomba S, Manguso F et al.. Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008; 68 88-93
- 13 Kelly C C, Lyall H, Petrie J R, Gould G W, Connell J M, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001; 86 2453-2455
- 14 Giallauria F, Orio F, Lombardi G et al.. Relationship between heart rate recovery and inflammatory markers in patients with polycystic ovary syndrome: a cross-sectional study. J Ovarian Res. 2009; 2 3
- 15 Rossi B, Sukalich S, Droz J et al.. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93 4780-4786
- 16 Barbieri R L, Makris A, Randall R W, Daniels G, Kistner R W, Ryan K J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986; 62 904-910
- 17 Nestler J E, Powers L P, Matt D W et al.. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991; 72 83-89
- 18 Nestler J E, Jakubowicz D J, de Vargas A F, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998; 83 2001-2005
- 19 Codner E, Iñíguez G, Villarroel C et al.. Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. J Clin Endocrinol Metab. 2007; 92 4742-4746
- 20 Codner E, Escobar-Morreale H F. Clinical review: hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2007; 92 1209-1216
- 21 Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E, Koutsilieris M. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). J Steroid Biochem Mol Biol. 2008; 109 242-246
- 22 Legro R S, Gnatuk C L, Kunselman A R, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005; 90 3236-3242
-
23 Zawadski J, Dunaif A.
Diagnostic criteria for polycystic ovary syndrome . In: Dunaif A, Givens JR, Haseltine FP, Merriam GR Polycystic Ovary Syndrome. Boston, MA; Blackwell Scientific 1992: 377-384 - 24 Azziz R, Carmina E, Dewailly D Androgen Excess Society et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91 4237-4245
- 25 Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006; 91 781-785
- 26 Auchus R J, Rainey W E. Adrenarche - physiology, biochemistry and human disease. Clin Endocrinol (Oxf). 2004; 60 288-296
- 27 Flück C E, Miller W L, Auchus R J. The 17, 20-lyase activity of cytochrome p450c17 from human fetal testis favors the delta5 steroidogenic pathway. J Clin Endocrinol Metab. 2003; 88 3762-3766
- 28 Doi S A, Al-Zaid M, Towers P A, Scott C J, Al-Shoumer K A. Steroidogenic alterations and adrenal androgen excess in PCOS. Steroids. 2006; 71 751-759
- 29 Nakajin S, Shively J E, Yuan P M, Hall P F. Microsomal cytochrome P-450 from neonatal pig testis: two enzymatic activities (17 alpha-hydroxylase and c17,20-lyase) associated with one protein. Biochemistry. 1981; 20 4037-4042
- 30 Lin D, Harikrishna J A, Moore C C, Jones K L, Miller W L. Missense mutation serine106----proline causes 17 alpha-hydroxylase deficiency. J Biol Chem. 1991; 266 15992-15998
- 31 Zuber M X, Simpson E R, Waterman M R. Expression of bovine 17 alpha-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science. 1986; 234 1258-1261
- 32 Penning T M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev. 1997; 18 281-305
- 33 Nelson V L, Qin K N, Rosenfield R L et al.. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001; 86 5925-5933
- 34 Carbunaru G, Prasad P, Scoccia B et al.. The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J Clin Endocrinol Metab. 2004; 89 783-794
- 35 Loughlin T, Cunningham S, Moore A, Culliton M, Smyth P P, McKenna T J. Adrenal abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab. 1986; 62 142-147
- 36 Kumar A, Woods K S, Bartolucci A A, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2005; 62 644-649
- 37 Carmina E, Lobo R A. Pituitary-adrenal responses to ovine corticotropin-releasing factor in polycystic ovary syndrome and in other hyperandrogenic patients. Gynecol Endocrinol. 1990; 4 225-232
- 38 Gonzalez F. Adrenal involvement in polycystic ovary syndrome. Semin Reprod Endocrinol. 1997; 15 137-157
- 39 Carmina E, Gonzalez F, Chang L, Lobo R A. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. Obstet Gynecol. 1995; 85 971-976
- 40 Matteri R K, Stanczyk F Z, Cassidenti D L, Paulson R J, Lobo R A. The ovarian contribution to peripherally derived serum C19 conjugates. J Clin Endocrinol Metab. 1992; 75 768-772
- 41 Gonzalez F, Hatala D A, Speroff L. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome. Am J Obstet Gynecol. 1991; 165 535-545
- 42 Kahsar-Miller M, Boots L R, Bartolucci A, Azziz R. Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertil Steril. 2004; 82 973-975
- 43 Witchel S F, Kahsar-Miller M, Aston C E, White C, Azziz R. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess. Fertil Steril. 2005; 83 371-375
- 44 Guido M, Romualdi D, Suriano R et al.. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod. 2004; 19 534-539
- 45 Corbould A. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?. Diabetes Metab Res Rev. 2008; 24 520-532
- 46 Arner P. Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome. Biochimie. 2005; 87 39-43
- 47 Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006; 85 1319-1340
- 48 Kapoor D, Malkin C J, Channer K S, Jones T H. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005; 63 239-250
- 49 Ding E L, Song Y, Malik V S, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006; 295 1288-1299
- 50 Dunn J F, Nisula B C, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981; 53 58-68
- 51 Pugeat M, Crave J C, Elmidani M et al.. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol. 1991; 40 841-849
- 52 Khosla S. Editorial: sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action?. J Clin Endocrinol Metab. 2006; 91 4764-4766
- 53 Rosner W, Auchus R J, Azziz R, Sluss P M, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007; 92 405-413
- 54 Liu Y, Ding J, Bush T L et al.. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol. 2001; 154 489-494
- 55 Reinecke H, Bogdanski J, Woltering A et al.. Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. Am J Cardiol. 2002; 90 364-368
- 56 Bernini G P, Sgro' M, Moretti A et al.. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab. 1999; 84 2008-2012
- 57 Cascella T, Palomba S, De Sio I et al.. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. 2008; 23 153-159
- 58 Shpakov A O, Pertseva M N. Structural and functional characterization of insulin receptor substrate proteins and the molecular mechanisms of their interaction with insulin superfamily tyrosine kinase receptors and effector proteins. Membr Cell Biol. 2000; 13 455-484
- 59 DeFronzo R A, Jacot E, Jequier E, Maeder E, Wahren J, Felber J P. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 1981; 30 1000-1007
- 60 Abel E D, Peroni O, Kim J K et al.. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001; 409 729-733
- 61 Mahajan D K. Polycystic ovarian disease: animal models. Endocrinol Metab Clin North Am. 1988; 17 705-732
- 62 Mannerås L, Cajander S, Holmäng A et al.. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007; 148 3781-3791
- 63 Holmäng A, Svedberg J, Jennische E, Björntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol. 1990; 259(4 Pt 1) E555-E560
- 64 Holmäng A, Larsson B-M, Brzezinska Z, Björntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol. 1992; 262(6 Pt 1) E851-E855
- 65 Holmäng A, Niklasson M, Rippe B, Lönnroth P. Insulin insensitivity and delayed transcapillary delivery of insulin in oophorectomized rats treated with testosterone. Acta Physiol Scand. 2001; 171 427-438
- 66 Rincon J, Holmäng A, Wahlström E O et al.. Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Diabetes. 1996; 45 615-621
- 67 Bolduc C, Larose M, Yoshioka M et al.. Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression. J Mol Endocrinol. 2004; 33 429-444
- 68 Pedersen S B, Fuglsig S, Sjøgren P, Richelsen B. Identification of steroid receptors in human adipose tissue. Eur J Clin Invest. 1996; 26 1051-1056
- 69 Dieudonne M N, Pecquery R, Boumediene A, Leneveu M C, Giudicelli Y. Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. Am J Physiol. 1998; 274(6 Pt 1) C1645-C1652
- 70 Joyner J, Hutley L, Cameron D. Intrinsic regional differences in androgen receptors and dihydrotestosterone metabolism in human preadipocytes. Horm Metab Res. 2002; 34 223-228
- 71 Moghetti P, Tosi F, Castello R et al.. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab. 1996; 81 952-960
- 72 Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1990; 70 699-704
- 73 Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba A J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998; 83 2699-2705
- 74 Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson P O. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod. 1998; 13 2706-2711
- 75 Krotkiewski M, Landin K, Dahlgren E, Janson P O, Holm G. Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS. Gynecol Obstet Invest. 2003; 55 88-95
- 76 Elkind-Hirsch K E, Valdes C T, Malinak L R. Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertil Steril. 1993; 60 634-641
- 77 Cagnacci A, Paoletti A M, Arangino S, Melis G B, Volpe A. Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. Hum Reprod. 1999; 14 893-897
- 78 Lanzone A, Fulghesu A M, Andreani C L et al.. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. Hum Reprod. 1990; 5 143-149
- 79 Gadir A A, Khatim M S, Mowafi R S, Alnaser H M, Alzaid H G, Shaw R W. Hormonal changes in patients with polycystic ovarian disease after ovarian electrocautery or pituitary desensitization. Clin Endocrinol (Oxf). 1990; 32 749-754
- 80 Tropeano G, Liberale I, Vuolo I P et al.. Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin-like growth factor I and insulin levels in women with polycystic ovary syndrome. J Endocrinol Invest. 1997; 20 220-224
- 81 Zulian E, Sartorato P, Benedini S et al.. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005; 28 49-53
- 82 Gambineri A, Patton L, Vaccina A et al.. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006; 91 3970-3980
- 83 Gambineri A, Pelusi C, Genghini S et al.. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004; 60 241-249
- 84 Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril. 2008; 89 899-906
- 85 Florakis D, Diamanti-Kandarakis E, Katsikis I et al.. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obes (Lond). 2008; 32 692-699
- 86 Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93 2670-2678
- 87 Moran L, Norman R J. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004; 18 719-736
- 88 Moran L J, Brinkworth G D, Norman R J. Dietary therapy in polycystic ovary syndrome. Semin Reprod Med. 2008; 26 85-92
- 89 Palomba S, Giallauria F, Falbo A et al.. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod. 2008; 23 642-650
- 90 Moran L J, Noakes M, Clifton P M, Tomlinson L, Galletly C, Norman R J. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88 812-819
- 91 Norman R J, Davies M J, Lord J, Moran L J. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab. 2002; 13 251-257
- 92 Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod. 1996; 11 1884-1891
- 93 Guzick D S, Wing R, Smith D, Berga S L, Winters S J. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril. 1994; 61 598-604
- 94 Huber-Buchholz M M, Carey D G, Norman R J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999; 84 1470-1474
- 95 Clark A M, Ledger W, Galletly C et al.. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod. 1995; 10 2705-2712
- 96 Clark A M, Thornley B, Tomlinson L, Galletley C, Norman R J. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998; 13 1502-1505
- 97 Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG. 2006; 113 1203-1209
- 98 Kiddy D S, Hamilton-Fairley D, Bush A et al.. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992; 36 105-111
- 99 Hamilton-Fairley D, Kiddy D, Anyaoku V, Koistinen R, Seppälä M, Franks S. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf). 1993; 39 363-367
- 100 Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab. 2006; 31 384-391
- 101 Thomson R L, Buckley J D, Noakes M, Clifton P M, Norman R J, Brinkworth G D. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93 3373-3380
- 102 Vigorito C, Giallauria F, Palomba S et al.. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92 1379-1384
- 103 Giallauria F, Palomba S, Maresca L et al.. Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2008; 69 792-798
- 104 Orio F, Giallauria F, Palomba S et al.. Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. Clin Endocrinol (Oxf). 2008; 68 976-981
Orio FrancescoM.D. Ph.D.
Department of Molecular & Clinical Endocrinology and Oncology
University of Naples “Federico II,” Naples, Italy
eMail: francescoorio@virgilio.it